Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 17, 2022Recall is isolated to powder formulas, including Similac®, Alimentum ® and EleCare®, manufactured at the Sturgis, Mich., plantRecall does not include any metabolic deficiency nutrition formulasNo Abbott liquid formulas or other Abbott nutrition powders and brands are impactedParents or customers with impacted product should visit similacrecall.com or call +1-800-986-8540- Feb 7, 2022- Abbott's investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart- Proprietary implant-to-implant (i2i™) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate- Aveir DR is also specifically designed to be retrieved if therapy needs evolve
-
Feb 3, 2022- Abbott’s Proclaim™ dorsal root ganglion (DRG) neurostimulation system is the only FDA-approved DRG technology for the treatment of CRPS I and causalgia of the lower extremitiesi- UnitedHealthcare is the largest private health insurance company in the U.S, providing coverage for more than 44 million healthcare membersii
- Jan 26, 2022- Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent- Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter- Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent- Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent- Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent- R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets